论文部分内容阅读
目的:探讨支气管哮喘患者LL-37抗菌肽的表达水平与哮喘类型及治疗之间的关系。方法:选取于我院就诊的哮喘患者120例作为实验对象,并选择同期于我院体检的健康对照120例。对患者采用莫特罗/布地奈德进行治疗,用酶联免疫吸附试验法(ELISA)对其治疗前后血浆及痰液上清中的LL-37水平进行检测并对结果进行统计学分析。诱导痰嗜酸粒细胞(EOS)计数≥3%定义为EOS型哮喘,EOS计数<3%则定义为非EOS型哮喘。结果:哮喘组在治疗前后血浆中LL-37水平分别为3.3(11.3)与6.9(19.7)μg·L-1,差异有统计学意义(Z=-2.778,P=0.032);痰液上清中LL-37水平分别为30.1(162.5)与71.4(186.1)μg·L-1,差异有统计学意义(Z=-2.295,P=0.022)。与对照组相比,哮喘组治疗后血浆LL-37表达水平差异无统计学意义(P=0.425),其痰液上清的LL-37表达水平差异亦无统计学意义(P=0.433)。进一步分析发现LL-37水平仅在EOS型哮喘组治疗后显著增高,而非EOS型哮喘组治疗后LL-37水平则无明显变化。结论:EOS型哮喘患者LL-37的表达水平在莫特罗/布地奈德治疗之后显著增加。
Objective: To investigate the relationship between the expression of LL-37 antimicrobial peptide and the type and treatment of asthma in patients with bronchial asthma. Methods: A total of 120 asthmatic patients treated in our hospital were selected as experimental subjects and 120 healthy controls were selected in our hospital during the same period. The patients were treated with motterol / budesonide, the levels of LL-37 in plasma and sputum supernatant before and after treatment were detected by enzyme linked immunosorbent assay (ELISA), and the results were statistically analyzed. EOS-induced sputum eosinophils (EOS) counts ≥ 3% were defined as EOS-type asthma and EOS-count <3% was defined as non-EOS-type asthma. Results: The levels of LL-37 in the asthma group before and after treatment were 3.3 (11.3) and 6.9 (19.7) μg · L-1, respectively, with statistical significance (Z = -2.778, P = 0.032) LL-37 levels were 30.1 (162.5) and 71.4 (186.1) μg · L-1, respectively. The difference was statistically significant (Z = -2.295, P = 0.022). Compared with the control group, there was no significant difference in the expression of LL-37 in the asthma group (P = 0.425), and there was no significant difference in the LL-37 expression in the sputum supernatant (P = 0.433). Further analysis found that LL-37 levels were only significantly increased in the EOS-type asthma group after treatment, while non-EOS-type asthma group LL-37 levels after treatment there was no significant change. CONCLUSIONS: The expression level of LL-37 in EOS-type asthmatics was significantly increased after treatment with motterol / budesonide.